JP2019518739A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019518739A5 JP2019518739A5 JP2018559785A JP2018559785A JP2019518739A5 JP 2019518739 A5 JP2019518739 A5 JP 2019518739A5 JP 2018559785 A JP2018559785 A JP 2018559785A JP 2018559785 A JP2018559785 A JP 2018559785A JP 2019518739 A5 JP2019518739 A5 JP 2019518739A5
- Authority
- JP
- Japan
- Prior art keywords
- liposome
- lipid
- peg
- mol
- pegylated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002502 liposome Substances 0.000 claims 23
- 150000002632 lipids Chemical class 0.000 claims 20
- 229920001223 polyethylene glycol Polymers 0.000 claims 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 8
- 239000000556 agonist Substances 0.000 claims 8
- 102000002689 toll-like receptors Human genes 0.000 claims 6
- 108020000411 toll-like receptors Proteins 0.000 claims 6
- 230000028993 immune response Effects 0.000 claims 5
- 230000001264 neutralization Effects 0.000 claims 5
- 229940107161 Cholesterol Drugs 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 235000012000 cholesterol Nutrition 0.000 claims 4
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 102000038129 antigens Human genes 0.000 claims 3
- 108091007172 antigens Proteins 0.000 claims 3
- ZKWQSBFSGZJNFP-UHFFFAOYSA-N 1,2-Bis(dimethylphosphino)ethane Chemical compound CP(C)CCP(C)C ZKWQSBFSGZJNFP-UHFFFAOYSA-N 0.000 claims 2
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-Bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 claims 2
- FVXDQWZBHIXIEJ-LNDKUQBDSA-N 1,2-dilinoleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC FVXDQWZBHIXIEJ-LNDKUQBDSA-N 0.000 claims 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 2
- GZDFHIJNHHMENY-UHFFFAOYSA-N DMPC Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 claims 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N Dipalmitoylphosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 2
- YYGNTYWPHWGJRM-RUSDCZJESA-N Squalene Natural products C(=C\CC/C(=C\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)(\CC/C=C(\C)/C)/C YYGNTYWPHWGJRM-RUSDCZJESA-N 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 claims 1
- 229940031439 Squalene Drugs 0.000 claims 1
- 102100012087 TLR4 Human genes 0.000 claims 1
- 101700022711 TLR4 Proteins 0.000 claims 1
- 102100006355 TLR7 Human genes 0.000 claims 1
- 101700075266 TLR7 Proteins 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 230000002209 hydrophobic Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000015788 innate immune response Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 150000008105 phosphatidylcholines Chemical class 0.000 claims 1
- 230000004936 stimulating Effects 0.000 claims 1
- 0 CCC(*C(C(C)C(*NC(C)=CC)OC*)[C@@](C)C(C)C)=C Chemical compound CCC(*C(C(C)C(*NC(C)=CC)OC*)[C@@](C)C(C)C)=C 0.000 description 2
Claims (16)
- (a)コレステロール、
(b)非PEG化中性脂質、及び
(c)PEG化脂質であって、前記PEG化脂質中のPEGの平均分子量が約5000ダルトン以下である、前記PEG化脂質、
を含んでなるリポソーム。 - 前記PEG化脂質中のPEGの平均分子量が約750ダルトン〜約5000ダルトンの範囲である、又は前記PEG化脂質中のPEGの平均分子量が約2000ダルトン以下である、請求項1に記載のリポソーム。
- 前記PEG化脂質の脂質成分が中性脂質を含んでなる、請求項1又は2の何れか一項に記載のリポソーム。
- 前記PEG化脂質の脂質成分が、DSPE、DPPC、DOPC、DLPC、DMPC、DSPC、POPC、DPPE、又はDMPEである、請求項1〜3の何れか一項に記載のリポソーム。
- 前記非PEG化中性脂質が、DPPC、DOPC、DLPC、DMPC、DSPC、POPC、DPPE、又はDMPEである、請求項1〜4の何れか一項に記載のリポソーム。
- a) 前記リポソームが、約2℃〜約8℃の温度で1ヶ月以上の間安定である、及び/又は
b) 前記リポソームの多分散指数が約0.3以下で維持される、及び/又は
c) 前記リポソームのサイズが450nm未満又は約450nmである、
請求項1〜8の何れか一項に記載のリポソーム。 - 前記リポソーム中の前記PEG化脂質のモルパーセンテージ(mol%)が約1mol%〜約25mol%の範囲であり、前記リポソーム中のコレステロールのmol%が約1mol%〜約50mol%の範囲であり、前記リポソーム中の非PEG化脂質のモル%が約45mol%〜約98mol%の範囲である、請求項1〜6の何れか一項に記載のリポソーム。
- 非PEG化中性脂質:コレステロール:PEG化脂質の脂質モル比が約9.8:5.7:0.8又は約18:5.5:3である、請求項1〜7の何れか一項に記載のリポソーム。
- 前記リポソームが、少なくとも1つのTLRアゴニストをさらに含んでなり、任意に前記TLRアゴニストが疎水性尾部を含んでなり、又は前記少なくとも1つ以上のTLRアゴニストが3M−052又はGLAである、請求項1〜8の何れか一項に記載のリポソーム。
- 前記リポソームが、TLR4アゴニスト及びTLR7/8アゴニストを含んでなり、任意にGLA及び3M−052を含んでなる、請求項9に記載のリポソーム。
- 前記リポソームが抗原をさらに含んでなり、前記抗原が任意にH5N1又はLecAを含んでなる、請求項1〜11の何れか一項に記載のリポソーム。
- 対象において免疫応答を刺激又はTh1応答を誘発する方法であって、請求項1〜12の何れか一項に記載のリポソームを前記対象に投与し、それによって前記対象において免疫応答を刺激又はTh1応答を誘発することを含んでなる、前記方法。
- 前記免疫応答が非特異的免疫応答又は前記免疫応答が抗原特異的免疫応答である、請求項13に記載の方法。
- 請求項1〜13の何れか一項に記載のPEG化リポソームの製造方法であって、
(a)前記非PEG化中性脂質、前記PEG化脂質、及び前記コレステロールを有機溶媒中で混合することと、
(b)前記有機溶媒を蒸発させて脂質膜を得ることと、
(c)緩衝液中で前記脂質膜を再水和させることと、
(d)工程(c)の再水和生成物を超音波処理、顕微溶液化、又は押出することと、
を含んでなる前記方法。 - TLRアゴニスト、スクアレン、及び不飽和ホスファチジルコリンを含んでなり、TLRアゴニストが任意に3M−052である、水中油型エマルション。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022143788A JP2022177112A (ja) | 2016-05-16 | 2022-09-09 | Peg化リポソームおよび使用方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662337328P | 2016-05-16 | 2016-05-16 | |
US62/337,328 | 2016-05-16 | ||
PCT/US2017/032756 WO2017200957A1 (en) | 2016-05-16 | 2017-05-15 | Pegylated liposomes and methods of use |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022143788A Division JP2022177112A (ja) | 2016-05-16 | 2022-09-09 | Peg化リポソームおよび使用方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019518739A JP2019518739A (ja) | 2019-07-04 |
JP2019518739A5 true JP2019518739A5 (ja) | 2020-06-25 |
JP7195147B2 JP7195147B2 (ja) | 2022-12-23 |
Family
ID=58794159
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018559785A Active JP7195147B2 (ja) | 2016-05-16 | 2017-05-15 | Peg化リポソームおよび使用方法 |
JP2022143788A Pending JP2022177112A (ja) | 2016-05-16 | 2022-09-09 | Peg化リポソームおよび使用方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022143788A Pending JP2022177112A (ja) | 2016-05-16 | 2022-09-09 | Peg化リポソームおよび使用方法 |
Country Status (12)
Country | Link |
---|---|
US (2) | US11266602B2 (ja) |
EP (1) | EP3458028A1 (ja) |
JP (2) | JP7195147B2 (ja) |
KR (1) | KR102483033B1 (ja) |
CN (1) | CN109562057A (ja) |
AU (2) | AU2017268175B2 (ja) |
BR (1) | BR112018073676B1 (ja) |
CA (1) | CA3023672A1 (ja) |
IL (1) | IL263030A (ja) |
MX (1) | MX2018013640A (ja) |
WO (1) | WO2017200957A1 (ja) |
ZA (1) | ZA201807128B (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102483033B1 (ko) | 2016-05-16 | 2022-12-30 | 액세스 투 어드밴스드 헬스 인스티튜트 | 페길화된 리포솜 및 이의 용도 |
CN107998070A (zh) * | 2017-12-12 | 2018-05-08 | 南京中医药大学 | 一种复合磷脂传递体及其在制备经皮给药制剂中的应用 |
EP3886901A1 (en) * | 2018-11-29 | 2021-10-06 | GlaxoSmithKline Biologicals S.A. | Methods for manufacturing an adjuvant |
JP7487187B2 (ja) | 2018-12-17 | 2024-05-20 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | リポソームを含む製剤 |
CN110151702A (zh) * | 2019-06-24 | 2019-08-23 | 昆明医科大学 | 聚乙二醇修饰流感疫苗脂质体及其制备方法 |
US11679163B2 (en) | 2019-09-20 | 2023-06-20 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
KR102328531B1 (ko) * | 2020-01-23 | 2021-11-17 | 서울대학교산학협력단 | 체내 면역 세포 표적 황화수소 공여체 담지 리포좀을 포함하는 면역질환 치료 또는 예방용 약학 조성물 |
AU2021241355A1 (en) | 2020-03-23 | 2022-10-13 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
WO2022136952A1 (en) | 2020-12-23 | 2022-06-30 | Infectious Disease Research Institute | Solanesol vaccine adjuvants and methods of preparing same |
WO2022183120A1 (en) * | 2021-02-26 | 2022-09-01 | University Of Virginia Patent Foundation | Development of covid-19 vaccine using a dual tlr ligand liposome adjuvant |
EP4304567A1 (en) * | 2021-03-11 | 2024-01-17 | The Trustees of the University of Pennsylvania | Targeted therapeutic lipid nanoparticles and methods of use |
CN115737800B (zh) * | 2023-01-09 | 2023-05-23 | 江苏瑞科生物技术股份有限公司 | 一种复合脂质体佐剂及其制备方法 |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3598122A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US4286592A (en) | 1980-02-04 | 1981-09-01 | Alza Corporation | Therapeutic system for administering drugs to the skin |
US4314557A (en) | 1980-05-19 | 1982-02-09 | Alza Corporation | Dissolution controlled active agent dispenser |
US4379454A (en) | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
US4568343A (en) | 1984-10-09 | 1986-02-04 | Alza Corporation | Skin permeation enhancer compositions |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
FI861417A0 (fi) | 1985-04-15 | 1986-04-01 | Endotronics Inc | Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav. |
US4948587A (en) | 1986-07-08 | 1990-08-14 | Massachusetts Institute Of Technology | Ultrasound enhancement of transbuccal drug delivery |
US4767402A (en) | 1986-07-08 | 1988-08-30 | Massachusetts Institute Of Technology | Ultrasound enhancement of transdermal drug delivery |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
EP1088830A3 (en) | 1987-06-22 | 2004-04-07 | Medeva Holdings B.V. | Hepatitis b surface antigen particles |
US4780212A (en) | 1987-07-31 | 1988-10-25 | Massachusetts Institute Of Technology | Ultrasound enchancement of membrane permeability |
US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
GB2232892B (en) | 1988-02-23 | 1991-07-24 | John Mark Tucker | Occlusive body for administering a physiologically active substance |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
GB8819209D0 (en) | 1988-08-12 | 1988-09-14 | Research Corp Ltd | Polypeptide & dna encoding same |
US4999403A (en) | 1988-10-28 | 1991-03-12 | Exxon Chemical Patents Inc. | Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions |
HUT58804A (en) | 1988-12-16 | 1992-03-30 | James Cleland Paton | Process for producing pneumolysine mutants and pneumococcus vaccines |
SG48175A1 (en) | 1989-07-25 | 1998-04-17 | Smithkline Beecham Biolog | Novel antigens and method for their preparation |
US5256643A (en) | 1990-05-29 | 1993-10-26 | The Government Of The United States | Human cripto protein |
GB9106048D0 (en) | 1991-03-21 | 1991-05-08 | Smithkline Beecham Biolog | Vaccines |
DE122007000023I1 (de) | 1991-07-19 | 2007-08-09 | Univ Queensland St Lucia | Impfsstoff gegen Humanes Papillomavirus (typ 18) |
US5464387A (en) | 1991-07-24 | 1995-11-07 | Alza Corporation | Transdermal delivery device |
JP3954643B2 (ja) | 1991-11-16 | 2007-08-08 | グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム | マラリア原虫由来のCSおよびHBsAG間のハイブリッド蛋白質 |
DE122007000096I1 (de) | 1992-06-25 | 2008-03-27 | Papillomavirus vakzine | |
US5786148A (en) | 1996-11-05 | 1998-07-28 | Incyte Pharmaceuticals, Inc. | Polynucleotides encoding a novel prostate-specific kallikrein |
US5437951A (en) | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
DE122007000090I1 (de) | 1993-03-09 | 2008-03-27 | Univ Rochester | Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen |
KR100341341B1 (ko) | 1993-07-15 | 2002-11-25 | 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 | 이미다조[4,5-c]피리딘-4-아민 |
US6033928A (en) | 1993-11-02 | 2000-03-07 | Matsushita Electric Industrial Co., Ltd. | Method of manufacturing aggregate of semiconductor micro-needles |
US5885211A (en) | 1993-11-15 | 1999-03-23 | Spectrix, Inc. | Microporation of human skin for monitoring the concentration of an analyte |
US5458140A (en) | 1993-11-15 | 1995-10-17 | Non-Invasive Monitoring Company (Nimco) | Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers |
US5814599A (en) | 1995-08-04 | 1998-09-29 | Massachusetts Insitiute Of Technology | Transdermal delivery of encapsulated drugs |
US5688506A (en) | 1994-01-27 | 1997-11-18 | Aphton Corp. | Immunogens against gonadotropin releasing hormone |
US5457041A (en) | 1994-03-25 | 1995-10-10 | Science Applications International Corporation | Needle array and method of introducing biological substances into living cells using the needle array |
US5591139A (en) | 1994-06-06 | 1997-01-07 | The Regents Of The University Of California | IC-processed microneedles |
ATE325875T1 (de) | 1994-10-07 | 2006-06-15 | Univ Loyola Chicago | Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung |
JP3958360B2 (ja) | 1995-02-24 | 2007-08-15 | キャンタブ ファーマシューティカルズ リサーチ リミティド | 免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法 |
US5843464A (en) | 1995-06-02 | 1998-12-01 | The Ohio State University | Synthetic chimeric fimbrin peptides |
US5981215A (en) | 1995-06-06 | 1999-11-09 | Human Genome Sciences, Inc. | Human criptin growth factor |
US5618275A (en) | 1995-10-27 | 1997-04-08 | Sonex International Corporation | Ultrasonic method and apparatus for cosmetic and dermatological applications |
US5656016A (en) | 1996-03-18 | 1997-08-12 | Abbott Laboratories | Sonophoretic drug delivery system |
US5955306A (en) | 1996-09-17 | 1999-09-21 | Millenium Pharmaceuticals, Inc. | Genes encoding proteins that interact with the tub protein |
US7033598B2 (en) | 1996-11-19 | 2006-04-25 | Intrabrain International N.V. | Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal |
US5840871A (en) | 1997-01-29 | 1998-11-24 | Incyte Pharmaceuticals, Inc. | Prostate-associated kallikrein |
IL131539A0 (en) | 1997-02-25 | 2001-01-28 | Corixa Corp | Compounds for immunodiagnosis of prostate cancer and methods for their use |
CA2297374A1 (en) | 1997-07-21 | 1999-01-28 | North American Vaccine, Inc. | Modified immunogenic pneumolysin, compositions and their use as vaccines |
GB9717953D0 (en) | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
US7459524B1 (en) | 1997-10-02 | 2008-12-02 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, sequence and uses thereof |
EP2228385A1 (en) | 1997-11-28 | 2010-09-15 | Merck Serono Biodevelopment | Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection |
UA67760C2 (uk) | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки |
CA2584482C (en) | 1998-02-05 | 2012-03-27 | Smithkline Beecham Biologicals S.A. | Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination |
NZ507378A (en) | 1998-04-07 | 2002-12-20 | Corixa Corp | Fusion proteins of mycobacterium tuberculosis antigens and their uses |
GB2336310B (en) | 1998-04-14 | 2003-09-10 | Stowic Resources Ltd | Method of manufacturing transdermal patches |
JP2002511266A (ja) | 1998-04-15 | 2002-04-16 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | 腫瘍関連核酸及びその使用 |
US6322532B1 (en) | 1998-06-24 | 2001-11-27 | 3M Innovative Properties Company | Sonophoresis method and apparatus |
HUP0203035A3 (en) | 1998-07-14 | 2007-12-28 | Corixa Corp | Compositions and methods for therapy and diagnosis of prostate cancer |
US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
DE60014076T2 (de) | 1999-04-19 | 2005-10-13 | Glaxosmithkline Biologicals S.A. | Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid |
US6685699B1 (en) | 1999-06-09 | 2004-02-03 | Spectrx, Inc. | Self-removing energy absorbing structure for thermal tissue ablation |
JP4162813B2 (ja) | 1999-10-28 | 2008-10-08 | 久光製薬株式会社 | イオントフォレーシス装置 |
US6974588B1 (en) | 1999-12-07 | 2005-12-13 | Elan Pharma International Limited | Transdermal patch for delivering volatile liquid drugs |
US6908453B2 (en) | 2002-01-15 | 2005-06-21 | 3M Innovative Properties Company | Microneedle devices and methods of manufacture |
US6676961B1 (en) | 2002-03-06 | 2004-01-13 | Automated Carrier Technologies, Inc. | Transdermal patch assembly |
US7018345B2 (en) | 2002-12-06 | 2006-03-28 | Hisamitsu Pharmaceutical Co., Inc. | Iontophoresis system |
KR101494056B1 (ko) | 2003-10-03 | 2015-02-16 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 피라졸로피리딘 및 그의 유사체 |
DE102005032175A1 (de) | 2005-07-09 | 2007-01-18 | Krones Ag | Behälter-Behandlungsmaschine und Verfahren zum Laden und Entladen einer Behälter-Behandlungsmaschine |
DE502005002538D1 (de) | 2005-07-19 | 2008-03-06 | Holzapfel Gmbh & Co Kg Geb | Auftriebshilfe |
US9333250B2 (en) * | 2006-04-06 | 2016-05-10 | The Johns Hopkins University | Methods and compositions for treating bacterial infection |
ES2673046T3 (es) * | 2006-09-26 | 2018-06-19 | Infectious Disease Research Institute | Composición de vacuna que contiene un adyuvante sintético |
PL2510946T3 (pl) * | 2007-02-07 | 2015-12-31 | Univ California | Koniugaty syntetycznych agonistów tlr i ich zastosowania |
MX2009010800A (es) | 2007-04-04 | 2010-01-29 | Infectious Disease Res Inst Id | Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos. |
US8793881B2 (en) | 2008-08-15 | 2014-08-05 | Stanley Black & Decker, Inc. | Utility knife with blade lock |
KR20110050531A (ko) * | 2008-08-28 | 2011-05-13 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
WO2010094663A1 (en) * | 2009-02-17 | 2010-08-26 | Glaxosmithkline Biologicals S.A. | Inactivated dengue virus vaccine with aluminium-free adjuvant |
CA2764374C (en) | 2009-06-05 | 2019-11-19 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants |
WO2010143971A2 (en) * | 2009-06-08 | 2010-12-16 | Epitarget As | Lipophilic drug carrier |
TWI397428B (zh) * | 2009-12-29 | 2013-06-01 | Ind Tech Res Inst | 標的第四介白素受體之傳輸系統 |
ES2943385T3 (es) * | 2010-08-17 | 2023-06-12 | 3M Innovative Properties Company | Compuesto modificador de la respuesta inmunitaria lipidada y su uso médico |
AU2011295935B2 (en) * | 2010-08-31 | 2016-02-11 | Glaxosmithkline Biologicals S.A. | Pegylated liposomes for delivery of immunogen-encoding RNA |
JP6240077B2 (ja) * | 2011-10-06 | 2017-11-29 | イムノバクシーン・テクノロジーズ・インコーポレイテッドImmunovaccine Technologies Inc. | Tlr2を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用 |
US9370489B2 (en) | 2011-10-31 | 2016-06-21 | Mallinckrodt Llc | Combinational liposome compositions for cancer therapy |
WO2013086526A1 (en) * | 2011-12-09 | 2013-06-13 | The Regents Of The University Of California | Liposomal drug encapsulation |
PT2811981T (pt) * | 2012-02-07 | 2019-06-12 | Infectious Disease Res Inst | Formulações adjuvantes melhoradas que compreendem os agonistas de tlr4 e os seus métodos de utilização |
EP3939572B1 (en) | 2012-04-12 | 2024-03-27 | Yale University | Vehicles for controlled delivery of different pharmaceutical agents |
WO2014008406A2 (en) * | 2012-07-05 | 2014-01-09 | Children's Medical Center Corporation | The bacterial biofilm matrix as a platform for protein delivery |
US10039716B2 (en) * | 2013-03-13 | 2018-08-07 | Mallinckrodt Llc | Liposomal cisplatin compositions for cancer therapy |
SG11201606625RA (en) | 2014-02-14 | 2016-09-29 | Immune Design Corp | Immunotherapy of cancer through combination of local and systemic immune stimulation |
BE1022346A9 (fr) * | 2014-03-12 | 2016-10-07 | Glaxosmithkline Biologicals Sa | Compositions liposomales pour une administration mucosale |
CN105534908B (zh) * | 2016-01-15 | 2018-12-14 | 徐州医学院 | 一种包载核酸药物的具缺氧响应能力和放疗增敏功能脂质体 |
KR102483033B1 (ko) | 2016-05-16 | 2022-12-30 | 액세스 투 어드밴스드 헬스 인스티튜트 | 페길화된 리포솜 및 이의 용도 |
-
2017
- 2017-05-15 KR KR1020187034749A patent/KR102483033B1/ko active IP Right Grant
- 2017-05-15 US US16/098,619 patent/US11266602B2/en active Active
- 2017-05-15 JP JP2018559785A patent/JP7195147B2/ja active Active
- 2017-05-15 MX MX2018013640A patent/MX2018013640A/es unknown
- 2017-05-15 CN CN201780030294.4A patent/CN109562057A/zh active Pending
- 2017-05-15 WO PCT/US2017/032756 patent/WO2017200957A1/en unknown
- 2017-05-15 BR BR112018073676-7A patent/BR112018073676B1/pt active IP Right Grant
- 2017-05-15 CA CA3023672A patent/CA3023672A1/en active Pending
- 2017-05-15 EP EP17726411.6A patent/EP3458028A1/en not_active Withdrawn
- 2017-05-15 AU AU2017268175A patent/AU2017268175B2/en active Active
-
2018
- 2018-10-25 ZA ZA2018/07128A patent/ZA201807128B/en unknown
- 2018-11-15 IL IL263030A patent/IL263030A/en unknown
-
2021
- 2021-12-23 US US17/560,594 patent/US20220160632A1/en active Pending
-
2022
- 2022-09-09 JP JP2022143788A patent/JP2022177112A/ja active Pending
-
2023
- 2023-02-01 AU AU2023200515A patent/AU2023200515B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019518739A5 (ja) | ||
Tandrup Schmidt et al. | Liposome-based adjuvants for subunit vaccines: formulation strategies for subunit antigens and immunostimulators | |
EP3964200A1 (en) | Compositions and methods for delivery of therapeutic agents | |
Davidsen et al. | Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6, 6′-dibehenate)—a novel adjuvant inducing both strong CMI and antibody responses | |
AU2017225927B2 (en) | Orally administrable composition | |
Kersten et al. | Liposomes and ISCOMS | |
Lonez et al. | Cationic lipid nanocarriers activate Toll-like receptor 2 and NLRP3 inflammasome pathways | |
JP5836394B2 (ja) | 陽イオン性脂質を含む陰イオン性薬物伝達体およびその製造方法 | |
US20220023212A1 (en) | Stable formulations of lipids and liposomes | |
Chen et al. | Induction of cytotoxic T-lymphocytes and antitumor activity by a liposomal lipopeptide vaccine | |
US4117113A (en) | Immunological preparations | |
Liu et al. | A novel liposome adjuvant DPC mediates Mycobacterium tuberculosis subunit vaccine well to induce cell-mediated immunity and high protective efficacy in mice | |
FR2726764A1 (fr) | Adjuvant pour composition vaccinale | |
JP2012532200A5 (ja) | ||
Hussain et al. | Th1 immune responses can be modulated by varying dimethyldioctadecylammonium and distearoyl-sn-glycero-3-phosphocholine content in liposomal adjuvants | |
KR20160132088A (ko) | 점막 전달용 리포솜 조성물 | |
Obeid et al. | Examination of the effect of niosome preparation methods in encapsulating model antigens on the vesicle characteristics and their ability to induce immune responses | |
JP2019512551A (ja) | 薄肉シェル型ポリマーナノ粒子及びその使用 | |
JP2020526530A5 (ja) | ||
CN115335084A (zh) | 包含聚肌氨酸的rna颗粒 | |
Lendemans et al. | Cationic cage-like complexes formed by DC-cholesterol, Quil-A, and phospholipid | |
Kabarkouhi et al. | Liposome, nanoliposome and allied technologies in COVID-19 vaccines: key roles and functionalities | |
RU2018137866A (ru) | Пегилированные липосомы и способы их применения | |
Myschik et al. | Immunostimulatory lipid implants containing Quil-A and DC-cholesterol | |
HRP20230985T1 (hr) | Farmaceutske formulacije pegiliranih liposoma i faktora koagulacije krvi |